Citizens JMP lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $22 from $26 and keeps an Outperform rating on the shares. Bicycle reported Q1 results and provided corporate milestones, including the initiation of the Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer, which will enroll roughly 60 patients, the analyst tells investors in a research note. The firm continues to believe Bicycle shares represent a unique investment opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating
- Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c)